
Aytu BioScience AYTU
$ 2.71
-4.24%
Quarterly report 2025-Q3
added 11-13-2025
Aytu BioScience Cost of Revenue 2011-2026 | AYTU
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Aytu BioScience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.6 M | 16.1 M | 40.8 M | 44.4 M | 36.4 M | 8.28 M | 2.2 M | 2.05 M | 1.42 M | 957 K | 88.1 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.4 M | 88.1 K | 15.8 M |
Quarterly Cost of Revenue Aytu BioScience
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.7 M | - | 5.65 M | 5.44 M | 4.59 M | - | 3.66 M | 4.14 M | 4.78 M | - | 9.99 M | 8.99 M | 9.62 M | 18.6 M | 11.5 M | 10.8 M | 9.44 M | 20.3 M | 13.9 M | 6.25 M | 4.06 M | 6 M | 3.82 M | 606 K | 376 K | 606 K | 376 K | 525 K | 411 K | 525 K | 411 K | 385 K | 287 K | 385 K | 287 K | 551 K | 192 K | 551 K | 192 K | 244 K | 37.3 K | 244 K | 37.3 K | - | 225 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.3 M | 225 | 4.23 M |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
32.2 M | - | 2.43 % | $ 254 M | ||
|
Aclaris Therapeutics
ACRS
|
2.79 M | $ 2.69 | 0.19 % | $ 208 M | ||
|
Ascendis Pharma A/S
ASND
|
3.52 M | $ 208.25 | -2.36 % | $ 5 B | ||
|
AgeX Therapeutics
AGE
|
40 K | - | -10.17 % | $ 12.2 K | ||
|
Albireo Pharma
ALBO
|
1.36 M | - | -0.23 % | $ 916 M | ||
|
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
369 K | - | -11.43 % | $ 502 K | ||
|
AIkido Pharma
AIKI
|
9 K | - | 1.93 % | $ 17.4 M | ||
|
Acasti Pharma
ACST
|
76 K | - | 4.01 % | $ 150 M | ||
|
BioNTech SE
BNTX
|
2.91 B | $ 98.56 | -1.52 % | $ 27.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
358 M | $ 27.72 | 1.43 % | $ 1.34 B | ||
|
CureVac N.V.
CVAC
|
238 M | - | - | $ 867 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
91.7 M | $ 11.49 | -2.21 % | $ 743 M | ||
|
BioDelivery Sciences International
BDSI
|
23.4 M | - | -4.8 % | $ 255 M | ||
|
Axon Enterprise
AXON
|
841 M | $ 611.74 | -1.48 % | $ 46.3 B | ||
|
Ayala Pharmaceuticals
AYLA
|
602 K | - | - | $ 7.46 M | ||
|
BeiGene, Ltd.
BGNE
|
70.7 M | - | 0.49 % | $ 251 B | ||
|
AstraZeneca PLC
AZN
|
12.4 B | $ 94.15 | -1.06 % | $ 96.9 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
436 K | - | -9.72 % | $ 5.89 M | ||
|
Acorda Therapeutics
ACOR
|
15.3 M | - | -24.86 % | $ 820 K | ||
|
BioVie
BIVI
|
312 K | $ 1.3 | -4.07 % | $ 1.92 M | ||
|
Berkeley Lights
BLI
|
24.8 M | - | -7.31 % | $ 87 M | ||
|
Biogen
BIIB
|
2.31 B | $ 185.27 | -0.88 % | $ 27 B | ||
|
bluebird bio
BLUE
|
33.5 M | - | - | $ 546 M | ||
|
ADiTx Therapeutics
ADTX
|
627 K | $ 0.84 | -0.24 % | $ 11.1 K | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M |